We have located links that may give you full text access.
Radiosynthesis of no-carrier-added meta-[(124)I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma.
Meta-iodobenzylguanidine (mIBG) has been radiolabelled at the no-carrier-added level with [(124)I] for a proof of concept study to assess the diagnostic accuracy of [(124)I]mIBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of mIBG was achieved via the iododesilylation reaction between [(124)I]sodium iodide and meta-trimethylsilylbenzylguanidine. [(124)I]mIBG was produced in 62-70 % radioiodide incorporation yield from [(124)I]sodium iodide. The average amount of formulated [(124)I]mIBG was 359 MBq (range 344-389 MBq) with an average specific radioactivity of 4.1 TBq μmol(-1) (range 1.8-5.9 TBq μmol(-1)) at end of synthesis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app